Our lab recently identified the widely clinically used anti-depressant sertraline as a potent SHMT inhibitor that selectively inhibits proliferation of serine synthesis addicted breast cancer and RPL10 R98S T-ALL cells [5]. Here, SHMT2 is linked to breast carcinoma.